CRVS Corvus Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing targeted immune cell protein inhibitors for immune-mediated diseases, inflammatory diseases, and cancers
• • New emphasis: Soquelitinib advanced to Phase 3 trial for relapsed peripheral T cell lymphoma (PTCL) and initiated Phase 2 trial for moderate-to-severe atopic dermatitis

Risk Factors

• • Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY
• • Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028

Management Discussion & Analysis

• • No revenue or profitability figures disclosed in MD&A section
• • No segment performance data available

Risk Factors

• • New risk: EU Clinical Trials Regulation fully effective Jan 31, 2025; centralized trial approvals via EU portal may impact development plans
• • Updated risk: Cash $65.7M insufficient to fund operations beyond 12 months from 10-Q date; risk of delays or termination of clinical trials without new financing

What are the latest CRVS SEC filings in 2026?

Corvus Pharmaceuticals, Inc. (CRVS) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CRVS file its most recent 10-K annual report?

Corvus Pharmaceuticals, Inc. (CRVS) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CRVS 10-Q quarterly reports?

Corvus Pharmaceuticals, Inc. (CRVS)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every CRVS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CRVS filed recently?

Corvus Pharmaceuticals, Inc. (CRVS)'s most recent 8-K was filed on April 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CRVS insider trading activity (Form 4)?

SignalX aggregates every CRVS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CRVS file with the SEC?

Corvus Pharmaceuticals, Inc. (CRVS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CRVS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Corvus Pharmaceuticals, Inc. (CRVS).

What is CRVS's SEC CIK number?

Corvus Pharmaceuticals, Inc. (CRVS)'s SEC CIK (Central Index Key) number is 1626971. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1626971 to look up all CRVS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CRVS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Corvus Pharmaceuticals, Inc. (CRVS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.